AbbVie Steps Deeper Into Obesity Market With New Phase 1 ABBV-295 Trial

Abbvie (ABBV) announced an update on their ongoing clinical study.

AbbVie is running a Phase 1 trial called “A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABBV-295 in Healthy Japanese Subjects With Overweight or Obesity.” The study aims to track side effects and how the body handles ABBV-295, an injection being tested as a potential treatment option in the fast-growing weight management space.

The main treatment is ABBV-295, given as an injection under the skin. The goal is to see if regular doses are safe and well tolerated in Japanese adults with excess weight, and to build early data that could support larger studies if results look promising.

This is an interventional study where volunteers are randomly placed into different groups. It uses a parallel design with some people getting ABBV-295 and others getting a placebo, and both participants and study staff are blinded so expectations do not influence the outcomes, with safety as the primary focus.

Participants will receive ABBV-295 or placebo injections for 12 weeks in each part of the study. The trial is currently listed as recruiting, and the most recent update was posted on April 13, 2026, signaling that the protocol is active and AbbVie is moving ahead with early-stage testing.

For investors, this update marks AbbVie’s push into obesity, a market led by Novo Nordisk and Eli Lilly that has driven strong valuations across the sector. While Phase 1 data will not move earnings near term, clear progress here could support sentiment on AbbVie’s longer-term growth story if ABBV-295 advances toward later-stage trials.

The study remains ongoing with the latest details and any future changes available on the ClinicalTrials.gov portal under the listed trial identifier.

To learn more about ABBV’s potential, visit the Abbvie drug pipeline page.